(2026). Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China. Health Economics Review.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Cost-effectiveness of Zanubrutinib Versus Ibrutinib in the First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)/small Lymphocytic Lymphoma (SLL) in China."
Health Economics Review 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Cost-effectiveness of Zanubrutinib Versus Ibrutinib in the First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)/small Lymphocytic Lymphoma (SLL) in China."
Health Economics Review, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.